Do you know what “biosimilar” means?
Biologics, which have received an extraordinary amount of research funding in recent years, have begun to take centre stage within the pharmaceutical industry. Extensive use of biologic products have become the mainstay in personal treatment regimens across an ever increasing array of diseases. The European Medicines Agency received recently the first marketing authorization application for a biosimilar monoclonal antibody (mAb) and adopted the final guidelines on biosimilar mAbs and Fc-fusion proteins. The agency requires high similarity between biosimilar and reference products for approval. “EuPA proteomics academy” will provide you a comprehensive high-level training program will provide a first insight what biotherapeutics are, what they do, and why the LC-MS characterization is so important.